These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12406086)

  • 1. Autologous lymphocytes as vectors to target therapeutic radiation, using indium-114m, in patients with lymphoid cell malignancy.
    Cowan RA; Murby B; Gunton D; Owens SE; Hoyes KP; Sharma HL; Smith AM; Chang J; van Kessel B; Nuttall PM; Crowther D
    Br J Haematol; 2002 Nov; 119(2):459-66. PubMed ID: 12406086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of lymphoid cell malignancy with In-114m labelled autologous lymphocytes.
    Sharma HL; Cowan RA; Murby B; Owens S; Nuttall PM; Gunton D; Smith AM; Chang J; Crowther D
    Anticancer Res; 1997; 17(3B):1815-21. PubMed ID: 9179239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow toxicity in mice treated with indium-114m-labelled blood cells.
    Hoyes KP; Wadeson PJ; Murby B; Sharma HL; Cowan RA; Lord BI
    J Exp Clin Cancer Res; 2001 Dec; 20(4):505-10. PubMed ID: 11876543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The behavior of autologous indium-114m-labeled lymphocytes in patients with lymphoid cell malignancy.
    Hamilton D; Cowan RA; Sharma HL; Drayson M; Nuttall PM; Wagstaff J; Deakin DP; Crowther D
    J Nucl Med; 1988 Apr; 29(4):485-93. PubMed ID: 3127553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The carriage and delivery of substances to lymphatic tissues by recirculating lymphocytes. II. Long-term selective irradiation of the spleen and lymph nodes by deposition of indium-114m.
    Birch M; Sharma HL; Bell EB; Ford WL
    Immunology; 1986 Jul; 58(3):359-64. PubMed ID: 3733144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
    Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
    DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
    Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 114Inm oxine-labelled lymphocytes--therapeutic applications.
    Hamilton D; Cowan RA; Drayson M; Sharma H; Cummins PE; Nuttall PM; Deakin D; Wagstaff J; Crowther D
    Nucl Med Commun; 1988 Oct; 9(10):797-802. PubMed ID: 3145475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
    Shen S; DeNardo GL; Yuan A; Hartmann-Siantar C; O'Donnell RT; DeNardo SJ
    Cancer Biother Radiopharm; 2005 Dec; 20(6):662-70. PubMed ID: 16398618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.
    Shen S; DeNardo GL; O'Donnell RT; Yuan A; DeNardo DA; DeNardo SJ
    Cancer; 1997 Dec; 80(12 Suppl):2553-7. PubMed ID: 9406709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
    Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
    J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
    Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation.
    Vose JM; Bierman PJ; Loberiza FR; Bociek RG; Matso D; Armitage JO
    Leuk Lymphoma; 2007 Apr; 48(4):683-90. PubMed ID: 17454625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.